The Vet Is In

A veterinarian in South Australia turned away a dying gull this month. Not from indifference — from protocol. The bird carried a suspected H5 infection, the clinic lacked the isolation capacity to safely intake it, and the decision, once made, was not really hers. It was made years earlier, by an industry that had already decided how many hospitals would exist, who would own them, and how thin their margins for emergency capacity would run.

The virus does not respect ownership structure. H5N1 is now present on all seven continents, active in more than 50 countries in a single season, moving through poultry, wild birds, seals, cats, and cattle. In the Southern Hemisphere, nearly half the world's female breeding population of southern elephant seals may already be dead. In Australia, the wave arrived this year and has not slowed. Vets are turning away injured wildlife as detections climb, and the country's Emergency Animal Disease Hotline has logged more than 21,000 calls since the outbreak began.

The instinct is to read this as a natural-disaster story — a virus, a die-off, a strained system responding as best it can. That reading misses the antecedent. The system was not strained by the virus. It was already thin, by design, before the virus arrived.

For most of the last century, veterinary medicine was a cottage industry — a doctor, a storefront, a town. That has changed faster than almost any other category adjacent to healthcare.

Private-equity and corporate ownership of US clinics grew from roughly 8 percent of clinics in 2011 to approximately 50 percent by 2025.

One buyer now dwarfs the rest of the field. Mars Veterinary Health alone operates nearly 3,000 hospitals worldwide, spanning Banfield, VCA, BluePearl, AniCura, and Linnaeus. BluePearl's remaining independence ended this June, when it agreed to join Mars Petcare fully. The company behind M&M's and Pedigree kibble is now, by revenue, more of a healthcare conglomerate than a candy company — pet care has outgrown Mars's confectionery division, on revenues that climbed from roughly $45 billion in 2022 to $55 billion in 2025.

Mars Veterinary Health alone operates nearly 3,000 hospitals worldwide.

Consolidation of ownership is not, on its own, an indictment. Centralized capital can build isolation wards, fund diagnostics, and standardize care that an independent storefront never could. But centralized ownership also means centralized risk tolerance. A decision about whether to accept a possibly infected wild bird into a clinic is no longer a single doctor's clinical judgment, weighed against a single building's resources. It is a policy question, set by an entity managing liability and margin across thousands of locations at once. When the policy says no, three thousand doors say no in unison.

Veterinary medicine's next entry point for pet owners is no longer the phone book, or even a plain web search. It is an AI answer engine — and that channel has consolidated even faster than clinic ownership itself.

Mars Petcare brands alone now capture between 27 and 30 percent of all veterinary AI citations across ChatGPT, Claude, Perplexity, and Google AI Overviews.

Roughly 80 percent of independent practices have zero AI visibility in their own metro area. A worried pet owner typing a symptom into a chatbot at 11 p.m. is now more likely to be routed to a Mars-owned hospital than to the independent clinic three blocks closer, simply because Mars has the review density, the structured data, and the editorial infrastructure that AI systems are built to trust.

Mars is not merely benefiting from this shift passively. It is building the infrastructure itself. Mars Science & Diagnostics, working with Microsoft Azure, has developed RapidRead, an AI tool built to help veterinary radiologists interpret imaging faster, layered on top of Antech, the reference laboratory network Mars already owns and that most non-Mars clinics still depend on for basic diagnostics. The company that decides how a triage case gets handled during an outbreak is, increasingly, the same company training the models that decide which vet a frightened pet owner finds at all.

None of this is conspiratorial. It is simply what vertical integration looks like once it has had two decades to compound: one owner across the hospitals, the labs, and now the discovery layer that sits in front of all of it.

For an independent veterinarian working inside this landscape — as most working vets in the United States and Australia now are not — the outbreak is where the compounding becomes visible in real time. A clinic within a large network operates on protocols written above the clinic level, protocols built for average-case liability rather than any single outbreak, in any single region, on any single week. When the protocol and the emergency diverge, the veterinarian is left holding the gap between what she is trained to do and what she is permitted to do.

This is not a story about villainy. It is a story about incentive structures reaching their logical endpoint at the worst possible moment. A consolidated industry optimizes for consistency, liability management, and scale — reasonable goals in ordinary years. An outbreak is not an ordinary year. It requires exactly what consolidation tends to remove: local discretion, surplus capacity, and doctors empowered to make case-by-case calls without waiting on policy set thousands of miles away.

The bird flu did not create this vulnerability. It found it.